PDA TR 81 focuses on the development of a risk-based control strategy adapted to cell-based therapy that can mitigate the risk of generating a product of poor quality.
More Standards PDF
PEI RP300-19
$197.00 $395.00
PEI RP500-19
$197.00 $395.00
PIP PNSMV054
$50.00 $100.00
PIP PNSMV053
$50.00 $100.00